123 related articles for article (PubMed ID: 22574367)
1. [Expression of PIM-1 in prostate cancer tissue and its relationship with PSA recurrence].
Zhang CT; Xu Y; Luo F; Zhang ZH; Liu RL; Yang K; Ma BJ
Zhonghua Nan Ke Xue; 2012 Apr; 18(4):323-6. PubMed ID: 22574367
[TBL] [Abstract][Full Text] [Related]
2. Detection of pim-1 mRNA in prostate cancer diagnosis.
He HC; Bi XC; Dai QS; Wang SS; Wei HA; Zhong WD; Liu WH; Jiang FN; Liu LS
Chin Med J (Engl); 2007 Sep; 120(17):1491-3. PubMed ID: 17908456
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues].
Zhen B; Shen Y; Zhang YM; Zhu CH; Liu ZL
Zhonghua Nan Ke Xue; 2006 May; 12(5):416-20. PubMed ID: 16755871
[TBL] [Abstract][Full Text] [Related]
4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
5. [P53 expression and its clinical significance in prostatic carcinoma].
Jiang T; Jiang H; Song XS; Li XC; Li QL
Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492
[TBL] [Abstract][Full Text] [Related]
6. [Vinculin and the androgen receptor in prostate cancer: expressions and correlations].
Zhu LY; Zhong KB; Lu SX; He LY
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):794-8. PubMed ID: 21171262
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
8. The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.
Ren K; Gou X; Xiao M; Wang M; Liu C; Tang Z; He W
Prostate; 2013 Sep; 73(13):1462-9. PubMed ID: 23813671
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma].
Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337
[TBL] [Abstract][Full Text] [Related]
10. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
[TBL] [Abstract][Full Text] [Related]
11. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
12. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
15. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
16. [Expression of VEGF in prostate cancer and its correlation with ET-1].
Zhou WQ; Yin HL; Zhang ZY; Yi XM; Ge JP; Zhou SG; Cheng W; Wei W; Ma HQ; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):987-92. PubMed ID: 19102498
[TBL] [Abstract][Full Text] [Related]
17. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
20. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?
Ang J; Lijovic M; Ashman LK; Kan K; Frauman AG
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1717-21. PubMed ID: 15533898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]